The University of Oxford determined that there is no benefit to Covid-19 patients and rather found that dexamethasone can significantly reduce mortality.
The World Health Organization (WHO) announced this Wednesday, June 17, the definitive cessation of clinical trials with hydroxychloroquine in the treatment of patients with coronavirus.
Ana María Henao, director of the WHO Action Plan for Research and Development, noted that the decision was made after the publication of the trials sponsored by the entity, as well as by the University of Oxford.
Countries like the United States that endorsed its use also had to suspend it after determining risk factors for patients with Covid-19.
Henao noted that the two investigations have shown that the use of hydroxychloroquine “does not reduce the mortality of patients with coronavirus.”
In late May and early June, the WHO already stopped trials with this drug, but resumed them once the authors of an article published in the journal “The Lancet”, which warned of an increase in the mortality of patients with Covid -19, retracted.
Along with this publication, trials carried out by the University of Oxford showed that treatment with hydroxychloroquine did not generate any benefit for patients infected with the new virus.
In addition, the university center discovered that the use of dexamethasone can considerably reduce mortality in severely Cobid-19 patients.
Be the first to comment